Global Acute Migraine Medication Market Size, Share, and Trends Analysis Report, By Type (Triptans, NSAIDs, and Others), By Distribution Channel (Offline Channel and Online Channel) Forecast Period (2022-2028)  

The global acute migraine medication market is anticipated to grow at a significant CAGR of 12.6% during the forecast period (2022-2028). Migraine is a neurological condition characterized by headaches, nausea, inability to smell, heightened sensitivity to sound and light, and numbness, among other symptoms. These headaches develop on one side of the head and last for varying lengths of time and intensity. Ergot alkaloids, triptans, and other migraine treatments are available in the acute migraine medication market. The growing awareness of the different types of migraines and the development of advanced treatment options are propelling the growth of the market.

Acute migrain is more prevalent in women as compared to men due to hormonal changes in them during menstrual cycle, pregnancy, menopause, and use of oral contraceptive pills. According to the article published by Migrain Research Foundation in March 2021, 18% of women in the US suffers from migrains while only 6% of men suffers from this disorder. In men, the prevalence of migrain is higher before puberty.

The market players are also contributing significantly in the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance,

• In September 2021, AbbVie Pharmaceuticals received FDA approval for QULIPTA, an oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine. QULIPTA is available in three strengths, including10 mg, 30 mg, and 60 mg.
• In June 2021, The Japanese Ministry of Health, Labour, and Welfare approved Aimovig (erenumab) for the prevention of migraine attacks in adults. It works by blocking the calcitonin gene-related peptide receptor (CGRP-R), whichplays a key role in migraine.
• In May 2020, Elyxyb(celecoxib oral solution), a drug developed by Dr. Reddy’s Laboratories, has been approved by the FDA. Elyxyb, formerly known as DFN-15, is used to treat individuals with acute migraine with or without aura.
• In October 2019, Lundbeck, a pharmaceutical company based in Denmark, acquired Alder BioPharmaceuticals, a pharmaceutical development firm based in Bothell, Washington.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape- Glaxo Smith Kline Plc, Astellas Pharma Inc., Amgen Inc., Bayer AG, AstraZeneca Plc, and Dr. Reddy’s Laboratories, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Acute Migraine Medication Market Report by Segment

By Type

• Triptans
• NSAIDs
• Others

By Distribution Channel

• Offline Channel
• Online Channel

Global Acute Migraine Medication Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa